312325-72-7

Usage

Uses

Used in Organic Synthesis:
2-(5-bromopyridin-2-yl)acetonitrile is used as a versatile building block for the synthesis of various organic compounds, leveraging its chemical structure to facilitate the creation of a wide array of products.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 2-(5-bromopyridin-2-yl)acetonitrile is utilized as an intermediate in the synthesis of biologically active molecules, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Development:
2-(5-bromopyridin-2-yl)acetonitrile is employed as a key component in the production of agrochemicals, playing a role in the formulation of substances that can enhance crop protection and yield.
Used in Fine Chemicals Manufacturing:
2-(5-bromopyridin-2-yl)acetonitrile is used as a building block in the manufacturing of fine chemicals, which are high-purity chemicals used in various specialized applications, including research, medical, and industrial processes.
Used in Medicinal Chemistry and Drug Discovery:
2-(5-bromopyridin-2-yl)acetonitrile is used as a valuable intermediate in medicinal chemistry for the exploration and development of new pharmaceutical agents, potentially leading to the discovery of novel treatments and therapies.
Used in the Development of New Materials:
2-(5-bromopyridin-2-yl)acetonitrile may also be utilized in the research and development of new materials, where its unique properties could contribute to the creation of innovative substances with specialized applications.

InChI:InChI=1/C7H5BrN2/c8-6-1-2-7(3-4-9)10-5-6/h1-2,5H,3H2

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 75-05-8 acetonitrile 
• 831203-34-0 tert-butyl (5-bromo-2(1H)-pyridinylidene)cyanoacetate 
• 145218-19-5 5-bromo-2-(bromomethyl)pyridine 
• 7677-24-9 trimethylsilyl cyanide 
• 3430-13-5 5-bromo-2-methylpyridine 
• 168823-76-5 5-bromo-2-(chloromethyl)pyridine 
• 766-11-0 5-bromo-2-fluoropyridine 

Downstream Products

• 917023-06-4 methyl 2-(5-bromopyridin-2-yl)acetate 
• 1428761-14-1 methyl 2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetate 
• 1582261-90-2 2,2-dichloro-N-((1R,2S)-1-(4-(6-(cyanomethyl)pyridin-3-yl)phenyl)-3-fluoro-1-hydroxypropan-2-yl)acetamide 
• 827628-42-2 1-(5-bromopyridin-2-yl)cyclopropanecarboxylic acid 
• 827628-15-9 1-(5-bromopyridin-2-yl)cyclopropane-1-carbonitrile 

Relevant academic research and scientific papers

CYCLIC COMPOUNDS AND METHODS OF USING SAME

The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof which are MALT1 inhibitors. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.

PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS

The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them highly advantageous for use in therapy, particularly in the treatment or prevention of cancer, a neovascular eye disease, inflammatory pain, or an inflammatory disease, such as, e.g., multiple sclerosis, rheumatoid arthritis or endometriosis.

Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)

The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal. Herein we describe the discovery of two such clinical candidates that inhibit the tyrosine kinase Src. Compound 1 is a phase 3 clinical trial candidat

BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE

The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS

The present invention relates to novel imidazo[1,2-b]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS

The present invention relates to novel imidazo[1,2-b]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

Synthesis and structure-activity relationship studies of highly potent novel oxazolidinone antibacterials

Novel antibacterial biaryl oxazolidinones bearing an aza-, an oxa-, or a thiabicyclo[3.1.0]hex-6-yl ring system were synthesized, and their in vitro antibacterial activity and structure-activity relationships (SAR) were evaluated. Most of the synthesized

Facile cyanomethylation of bromopyridines by nucleophilic substitution with lithioacetonitrile

Substituted bromopyridines undergo facile nucleophilic substitution with lithioacetonitrile under mild conditions to afford the corresponding cyanomethylated products.